ClinicalTrials.gg
CompletedNCT00080223Updated Apr 17, 2017Results posted

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of Pirfenidone in Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 27 sites in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Other

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Aug 2003, registered Mar 2004).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
12th of 21
83 · median 89
Started
2003
the only one that year
Phase 2
6 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
5 of 21
Genentech, Inc.

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 12th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 2, and was the 1st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).

Read the detailed description

This study has been designed as a rollover study to collectively include safety data from various previous studies.

In addition, InterMune has also initiated an Early Access Program to make pirfenidone available to a limited number of patients with idiopathic pulmonary fibrosis in the United States. This program is also being conducted under this protocol. Registration of patients with documented IPF has been closed as of October 2005.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
  • Pulmonary Fibrosis

Keywords

  • pulmonary fibrosis
  • respiratory diseases
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  • Able to understand and sign an form
  • Understand the importance of adherence to study treatment and the study protocol, including concomitant medication restrictions, throughout the study period
  • Patients must be willing to travel to an approved regional center for all study-related visits

Roll-Over Criteria:

  • Entry into study through rollover has been completed

Criteria for Early Access Program patients:

  • Clinical symptoms consistent with IPF ≥3 months duration
  • Age 40 - 85, inclusive
  • At the time of registration with National Organization for Rare Disorders (NORD), patients with IPF must have a percent predicted forced vital capacity (FVC) of ≥50%, and percent predicted carbon monoxide diffusing capacity (DLCO) of ≥35%
  • At the time of enrollment in PIPF-002, (screening/baseline visit) percent predicted FVC must be ≥45%, and percent predicted DLCO must be ≥30%
  • High-resolution computed tomographic scan (HRCT) showing definite IPF. For patients with surgical lung showing definite or probable usual interstitial pneumonia (UIP), the HRCT criterion of probable IPF is sufficient
  • For patients aged \<50 years: open or video-assisted thoracoscopic (VATS) lung biopsy showing definite or probable UIP. In addition, no features supporting an alternative diagnosis on transbronchial biopsy or bronchoalveolar lavage if performed
  • For patients aged ≥50 years: at least one of the following diagnostic findings as well as the absence of any features on specimens resulting from any of these procedures that support an alternative diagnosis: 1) Open or VATS lung biopsy showing definite or probable UIP; 2) Transbronchial biopsy showing no features to support an alternative diagnosis; 3) Bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Pirfenidone

    up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study

    Drug: Pirfenidone

Interventions

  • up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were classified as severe (Grade 3) in following cases: marked limitation in activity; some assistance usually required; medical intervention/ therapy required, hospitalization possible. Treatment-emergent AEs were those occurring on or after the first dosing day and up to 28 days after discontinuation of study treatment, and those occurring before treatment that worsened after the first study dose. AE included serious as well as non-serious AEs.

    Time frame: Baseline to 28 days after the last dose of study treatment (maximum duration of treatment in study was 604 weeks)

Secondary outcomes

  1. Percent Predicted Forced Vital Capacity (FVC)

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out from the lungs after full inspiration in the upright position, measured in liters. Predicted FVC is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (actual FVC value in liter)/(predicted FVC) \* 100%

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480

  2. Hemoglobin (Hgb)-Corrected Percent-Predicted Carbon Monoxide Diffusing Capacity (DLco)

    DLco is a pulmonary function test, and measures the partial pressure difference between inspired and expired carbon monoxide. Predicted DLco is based on a formula using sex, age and height of a person. Predicted DLco = \[Hbg-corrected DLco value (in milliliters per minute per millimeter mercury \[mL/min/mmHg\])/predicted DLco\] \* 100%

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480

  3. Resting Oxygen Saturation by Pulse Oximetry (SpO2)

    SpO2 is the percentage of oxygen saturation in the blood. Oxygen level (oxygen saturation) of the blood was measured using pulse oximetry on room air.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480

  4. Overall Survival

    Survival was analyzed as time from first study dose to death (all-cause mortality) with surviving participants censored at their last available assessment.

    Time frame: First dosing of study treatment until death (up to 604 weeks)

07

Results

Posted Mar 9, 2016

Participant flow

Participant flow — Overall Study
MilestonePirfenidone
Started83
Completed7
Not completed76
Withdrew: Adverse event23
Withdrew: Death21
Withdrew: Withdrawal by subject13
Withdrew: Lung transplantation9
Withdrew: Non-compliance with study treatment7
Withdrew: Participant unwilling to continue2
Withdrew: Physician decision1

Outcome measures

PrimaryPercentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were classified as severe (Grade 3) in following cases: marked limitation in activity; some assistance usually required; medical intervention/ therapy required, hospitalization possible. Treatment-emergent AEs were those occurring on or after the first dosing day and up to 28 days after discontinuation of study treatment, and those occurring before treatment that worsened after the first study dose. AE included serious as well as non-serious AEs.

Time frame:
Baseline to 28 days after the last dose of study treatment (maximum duration of treatment in study was 604 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE
percentage of participantsPirfenidone
Any AE98.8
SAE59.0
Severe AE36.1
Life-threatening AE21.7
AEs leading to death25.3
AE leading to study treatment discontinuation43.4
SecondaryPercent Predicted Forced Vital Capacity (FVC)

FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out from the lungs after full inspiration in the upright position, measured in liters. Predicted FVC is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (actual FVC value in liter)/(predicted FVC) \* 100%

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480
Reported as:
Mean · percent predicted FVC
Percent Predicted Forced Vital Capacity (FVC)
percent predicted FVCPirfenidone
Baseline (n=78)67.7 ± 18.70
Week 24 (n=71)67.5 ± 17.11
Week 48 (n=57)68.7 ± 17.36
Week 72 (n=50)68.4 ± 16.20
Week 96 (n=47)67.9 ± 17.76
Week 120 (n=44)67.7 ± 18.03
Week 144 (n=39)66.1 ± 18.22
Week 168 (n=35)65.7 ± 17.74
Week 192 (n=28)67.8 ± 18.32
Week 216 (n=28)68.7 ± 21.97
Week 240 (n=22)65.3 ± 16.80
Week 264 (n=15)70.1 ± 13.26
Week 288 (n=14)76.6 ± 18.71
Week 312 (n=14)71.1 ± 14.03
Week 336 (n=10)64.9 ± 13.61
Week 360 (n=7)60.9 ± 15.00
Week 384 (n=6)68.4 ± 17.43
Week 408 (n=4)65.1 ± 11.84
Week 432 (n=1)61.5 ± NA
Week 456 (n=1)78.4 ± NA
Week 480 (n=1)80.9 ± NA
SecondaryHemoglobin (Hgb)-Corrected Percent-Predicted Carbon Monoxide Diffusing Capacity (DLco)

DLco is a pulmonary function test, and measures the partial pressure difference between inspired and expired carbon monoxide. Predicted DLco is based on a formula using sex, age and height of a person. Predicted DLco = \[Hbg-corrected DLco value (in milliliters per minute per millimeter mercury \[mL/min/mmHg\])/predicted DLco\] \* 100%

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480
Reported as:
Mean · percent predicted DLco
Hemoglobin (Hgb)-Corrected Percent-Predicted Carbon Monoxide Diffusing Capacity (DLco)
percent predicted DLcoPirfenidone
Baseline (n=74)38.0 ± 13.36
Week 24 (n=65)39.5 ± 13.56
Week 48 (n=55)37.1 ± 13.55
Week 72 (n=49)37.0 ± 12.01
Week 96 (n=44)38.0 ± 12.35
Week 120 (n=41)35.7 ± 12.55
Week 144 (n=37)38.5 ± 13.47
Week 168 (n=33)36.7 ± 12.98
Week 192 (n=27)37.2 ± 11.34
Week 216 (n=28)35.8 ± 11.31
Week 240 (n=22)35.5 ± 12.67
Week 264 (n=15)37.5 ± 9.69
Week 288 (n=14)42.9 ± 18.43
Week 312 (n=14)38.6 ± 9.54
Week 336 (n=10)33.7 ± 6.41
Week 360 (n=7)37.1 ± 11.19
Week 384 (n=5)38.3 ± 13.16
Week 408 (n=4)38.1 ± 9.41
Week 432 (n=1)33.9 ± NA
Week 456 (n=1)11.6 ± NA
Week 480 (n=1)38.9 ± NA
SecondaryResting Oxygen Saturation by Pulse Oximetry (SpO2)

SpO2 is the percentage of oxygen saturation in the blood. Oxygen level (oxygen saturation) of the blood was measured using pulse oximetry on room air.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480
Reported as:
Mean · percentage of oxygen saturation
Resting Oxygen Saturation by Pulse Oximetry (SpO2)
percentage of oxygen saturationPirfenidone
Baseline (n=72)94.5 ± 3.53
Week 24 (n=55)94.4 ± 4.14
Week 48 (n=47)94.8 ± 3.05
Week 72 (n=41)94.9 ± 3.01
Week 96 (n=36)94.9 ± 2.77
Week 120 (n=35)94.8 ± 2.46
Week 144 (n=33)94.8 ± 2.78
Week 168 (n=25)94.0 ± 3.18
Week 192 (n=22)94.9 ± 2.59
Week 216 (n=23)95.2 ± 2.33
Week 240 (n=17)95.5 ± 2.67
Week 264 (n=11)95.7 ± 1.56
Week 288 (n=10)94.6 ± 4.09
Week 312 (n=11)95.8 ± 2.48
Week 336 (n=9)94.4 ± 2.35
Week 360 (n=7)94.9 ± 4.02
Week 384 (n=7)94.0 ± 2.77
Week 408 (n=6)94.8 ± 2.86
Week 432 (n=1)95.0 ± NA
Week 456 (n=1)97.0 ± NA
Week 480 (n=3)95.0 ± 2.00
SecondaryOverall Survival

Survival was analyzed as time from first study dose to death (all-cause mortality) with surviving participants censored at their last available assessment.

Time frame:
First dosing of study treatment until death (up to 604 weeks)
Reported as:
Median · weeks
Overall Survival
weeksPirfenidone
Overall Survival508.7 (264.14 to NA)

Adverse events

Collected over Baseline to 28 days after the last dose of study treatment (maximum duration of treatment in study was 604 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone—49/83 (59%)81/83 (97.6%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPirfenidone
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders15/83
PneumoniaInfections and infestations9/83
Respiratory failureRespiratory, thoracic and mediastinal disorders6/83
Atrial fibrillationCardiac disorders4/83
DyspnoeaRespiratory, thoracic and mediastinal disorders4/83
Coronary artery diseaseCardiac disorders3/83
BronchitisInfections and infestations3/83
Cardiac failure congestiveCardiac disorders2/83
Myocardial infarctionCardiac disorders2/83
Colitis ischaemicGastrointestinal disorders2/83
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPirfenidone
NauseaGastrointestinal disorders40/83
FatigueGeneral disorders27/83
DyspnoeaRespiratory, thoracic and mediastinal disorders23/83
Upper respiratory tract infectionInfections and infestations21/83
CoughRespiratory, thoracic and mediastinal disorders21/83
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders21/83
Weight decreasedInvestigations18/83
RashSkin and subcutaneous tissue disorders16/83
InsomniaPsychiatric disorders15/83
Decreased appetiteMetabolism and nutrition disorders14/83

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(years)Pirfenidone
Mean68.5 ± 9.15
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone
Female23
Male60
08

Study locations

27 sites
  • Phoenix, Arizona 85006, United States
  • Pomona, California 91767, United States
  • San Jose, California 95119, United States
  • New Haven, Connecticut 06520, United States
  • Sarasota, Florida 34239, United States
  • Atlanta, Georgia 30322, United States
  • Kailua, Hawaii 96734, United States
  • Lahaina, Hawaii 96761, United States
  • Nampa, Idaho 83686, United States
  • Elk Grove Village, Illinois 60007, United States
  • Boston, Massachusetts 02118, United States
  • West Roxbury, Massachusetts 02132, United States
  • St. Louis, Missouri 63110, United States
  • Huntington Station, New York 11746, United States
  • New York, New York 10016, United States
  • New York, New York 10029-6574, United States
  • Rochester, New York 14620, United States
  • Worthington, Ohio 43085, United States
  • Portland, Oregon 97220, United States
  • Portland, Oregon 97227, United States
  • Lancaster, Pennsylvania 17601, United States
  • Dallas, Texas 75390-8503, United States
  • Houston, Texas 77005, United States
  • San Antonio, Texas 78229, United States
  • Provo, Utah 84604, United States
  • Annandale, Virginia 22003, United States
  • Bremerton, Washington 98310 - 3349, United States
09

References and documents

Publications

  • Gotfried MH, Girod CE, Antin-Ozerkis D, Burgess T, Strombom I, Stauffer JL, Kirchgaessler KU, Padilla ML. An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002). Pulm Ther. 2018 Jun;4(1):59-71. doi: 10.1007/s41030-018-0053-y. Epub 2018 Apr 5. PubMed 32026243 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2003 to primary completion in Apr 2015, 139 months.

Results were first posted in Mar 2016, 10 months after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 139 months is above that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2004
First posted
Mar 26, 2004
StartActual
Aug 31, 2003
Primary completionActual
Apr 30, 2015
CompletionActual
Apr 30, 2015
Results first posted
Mar 9, 2016
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00080223
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 26, 2004
Start date
Aug 31, 2003
Primary completion
Apr 30, 2015
Completion
Apr 30, 2015
Results posted
Mar 9, 2016
Last update
Apr 17, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion